Ipamorelin
Also known as: Ipam, Ipamorelin acetate, NBI‑31772, NNC 26-0161
Source Ipamorelin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Ipamorelin is a synthetic pentapeptide GH‑releasing peptide used primarily in research to study growth hormone physiology and potential anti‑aging or body‑composition benefits. It is not approved for clinical use in major jurisdictions.
Mechanism of Action
Selective agonist of the ghrelin receptor (GHSR) stimulating pulsatile growth hormone release without markedly affecting cortisol or prolactin levels
Routes of Administration
Goals & Uses
- Increase endogenous growth hormoneEndocrineModerate
- Enhance recovery after exercisePerformanceLow
- Body Composition Improvement (Lean Mass / Fat Loss)Metabolic / Body CompositionLow
- Improve body compositionMusculoskeletalLow
- Recovery and Tissue RepairRegenerative / RecoveryLow
- Increased Growth Hormone SecretionEndocrine / HormonalModerate
- Sleep Quality ImprovementNeurological / SleepLow
- Anti-aging / LongevityAgingLow
- Bone Density MaintenanceMusculoskeletalLow
Contraindications
- Active malignancyOncologyHighUse caution or avoid depending on agent and context
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Diabetic retinopathyOphthalmologyHigh
- Uncontrolled Diabetes MellitusMetabolic / EndocrineModerate
- LactationReproductiveHigh
- Pituitary Tumor or Hypothalamic DiseaseNeurological / EndocrineHigh
Adverse Effects
- Injection site reactionsLocalCommon
- Injection site painLocalCommonPain at the injection site
- HeadacheNeurologicUncommonPain in the head or upper neck
- Water retention / edemaFluid BalanceCommon
- FlushingVascularCommonWarmth and redness of the skin
- Transient hyperglycemiaMetabolic/EndocrineRare
- Transient HypoglycemiaMetabolicUncommon
- Elevated IGF-1EndocrineCommon
- DizzinessNeurologicUncommonFeeling faint, lightheaded, or unsteady
Drug Interactions
- Other GH secretagogues (e.g., GHRP‑2, GHRP‑6)Moderate
- InsulinModerateMay increase risk of low blood sugar
- Insulin / antidiabetic agentsModerate
- CJC-1295 / GHRH AnaloguesModerate
- CorticosteroidsLow
- Thyroid hormone replacementLow
Population Constraints
- Elderly (>65 years)AgeRelative
- Pediatric patientsAgeRelative
- Pediatrics (<18 years)AgeRelative
- Lactating IndividualsReproductiveAbsolute
- Patients with history of cancerOncologyRelative
- Patients with Insulin Resistance or Type 2 DiabetesMetabolicRelative
Regulatory Status
- European UnionUnapprovedNo marketing authorization; classified as a research chemical
- United StatesInvestigationalNot FDA‑approved; available only for research use
- United KingdomUnapprovedNot licensed for medicinal use; sold for laboratory research only
Not approved by the FDA, EMA, or other major regulatory agencies for human therapeutic use. In 2023–2024, the FDA moved to restrict compounding of ipamorelin/CJC-1295 combinations. It remains classified as a research compound. Frequently used off-label in anti-aging and performance medicine clinics via compounding pharmacies.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Ipamorelin?
Ipamorelin is a synthetic pentapeptide GH‑releasing peptide used primarily in research to study growth hormone physiology and potential anti‑aging or body‑composition benefits. It is not approved for clinical use in major jurisdictions.
What is Ipamorelin used for?
Ipamorelin is educationally associated with: Increase endogenous growth hormone, Enhance recovery after exercise, Body Composition Improvement (Lean Mass / Fat Loss), Improve body composition, Recovery and Tissue Repair, Increased Growth Hormone Secretion, Sleep Quality Improvement, Anti-aging / Longevity, Bone Density Maintenance. Educational only — not medical advice.
How is Ipamorelin administered?
Recorded routes of administration: Intravenous, Nasal, Subcutaneous.
What are the potential side effects of Ipamorelin?
Reported adverse effects include: Injection site reactions, Injection site pain, Headache, Water retention / edema, Flushing, Transient hyperglycemia, Transient Hypoglycemia, Elevated IGF-1, Dizziness. This list is not exhaustive — consult a qualified clinician.
Who should avoid Ipamorelin?
Recorded contraindications: Active malignancy, Pregnancy, Diabetic retinopathy, Uncontrolled Diabetes Mellitus, Lactation, Pituitary Tumor or Hypothalamic Disease. Consult a qualified clinician before use.